Twenty-five years after its approval by the FDA and EMA, tacrolimus remains the
cornerstone of immunosuppressive treatment following solid organ transplantation [1, 2] …

Aim: The once daily tacrolimus formulation (Tac-OD) has been associated with better patient
adherence and low variability in exposure. Patients carrying the CYP3A5* 1 allele show …

Tacrolimus (Tac) exhibits an interindividual pharmacokinetic variability that affects the dose
required to reach the target concentration in blood. Tac is metabolized by two enzymes of …

Background: Selection of expected phenotypes (ie, expressers/non-expressers) is currently
used in CYP3A5* 3 genotype-based tacrolimus dosing. The authors assessed whether a …

Aims Although cytochromeP450 (CYP) 3A5 gene polymorphism affects personalized
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

Abstract Background: Tacrolimus (Tac) is an immunosuppressive drug used to prevent post-
transplant (PT) organ rejection. Continuous Tac monitoring is necessary to adjust the dose …

Aims: Tacrolimus has a narrow therapeutic window and shows significant interindividual
difference in dose requirement. In this study we aim to first identify genetic factors that impact …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …

Tacrolimus is effective for the prevention of acute rejection, but is also highly toxic and has
great intra-and inter-individual variability in transplant patients. Genetic variation and other …